441 related articles for article (PubMed ID: 18607587)
1. Lysostaphin: an antistaphylococcal agent.
Kumar JK
Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
Desbois AP; Gemmell CG; Coote PJ
Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
[TBL] [Abstract][Full Text] [Related]
3. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
Kokai-Kun JF; Chanturiya T; Mond JJ
J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
LaPlante KL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
[TBL] [Abstract][Full Text] [Related]
5. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
Climo MW; Patron RL; Goldstein BP; Archer GL
Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
[TBL] [Abstract][Full Text] [Related]
6. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
Becker SC; Foster-Frey J; Donovan DM
FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
[TBL] [Abstract][Full Text] [Related]
7. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.
Kokai-Kun JF; Chanturiya T; Mond JJ
J Antimicrob Chemother; 2009 Jul; 64(1):94-100. PubMed ID: 19398455
[TBL] [Abstract][Full Text] [Related]
8. Surface disinfection properties of the combination of an antimicrobial peptide, ranalexin, with an endopeptidase, lysostaphin, against methicillin-resistant Staphylococcus aureus (MRSA).
Desbois AP; Lang S; Gemmell CG; Coote PJ
J Appl Microbiol; 2010 Feb; 108(2):723-30. PubMed ID: 19709343
[TBL] [Abstract][Full Text] [Related]
9. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
Graham S; Coote PJ
J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
[TBL] [Abstract][Full Text] [Related]
10. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.
Dajcs JJ; Thibodeaux BA; Girgis DO; Shaffer MD; Delvisco SM; O'Callaghan RJ
Invest Ophthalmol Vis Sci; 2002 Dec; 43(12):3712-6. PubMed ID: 12454041
[TBL] [Abstract][Full Text] [Related]
11. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
Kusuma CM; Kokai-Kun JF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
[TBL] [Abstract][Full Text] [Related]
12. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.
Shah A; Mond J; Walsh S
Antimicrob Agents Chemother; 2004 Jul; 48(7):2704-7. PubMed ID: 15215130
[TBL] [Abstract][Full Text] [Related]
13. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland.
Bramley AJ; Foster R
Res Vet Sci; 1990 Jul; 49(1):120-1. PubMed ID: 2382049
[TBL] [Abstract][Full Text] [Related]
14. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.
Howden BP; Grayson ML
Clin Infect Dis; 2006 Feb; 42(3):394-400. PubMed ID: 16392088
[TBL] [Abstract][Full Text] [Related]
15. Vancomycin: does it still have a role as an antistaphylococcal agent?
Deresinski S
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):393-401. PubMed ID: 17547504
[TBL] [Abstract][Full Text] [Related]
16. epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of peptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus.
Sugai M; Fujiwara T; Ohta K; Komatsuzawa H; Ohara M; Suginaka H
J Bacteriol; 1997 Jul; 179(13):4311-8. PubMed ID: 9209049
[TBL] [Abstract][Full Text] [Related]
17. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin.
Francius G; Domenech O; Mingeot-Leclercq MP; Dufrêne YF
J Bacteriol; 2008 Dec; 190(24):7904-9. PubMed ID: 18835985
[TBL] [Abstract][Full Text] [Related]
18. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.
Climo MW; Ehlert K; Archer GL
Antimicrob Agents Chemother; 2001 May; 45(5):1431-7. PubMed ID: 11302806
[TBL] [Abstract][Full Text] [Related]
19. [Topical use of lysostaphin for Staphylococcus aureus infection of burn wounds in mice].
Huan JN
Zhonghua Wai Ke Za Zhi; 1992 May; 30(5):270-1, 316. PubMed ID: 1289000
[TBL] [Abstract][Full Text] [Related]
20. Hydrogel delivery of lysostaphin eliminates orthopedic implant infection by
Johnson CT; Wroe JA; Agarwal R; Martin KE; Guldberg RE; Donlan RM; Westblade LF; García AJ
Proc Natl Acad Sci U S A; 2018 May; 115(22):E4960-E4969. PubMed ID: 29760099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
